SpringWorks Therapeutics Long Term Debt 2019-2022 | SWTX
SpringWorks Therapeutics long term debt from 2019 to 2022. Long term debt can be defined as the sum of all long term debt fields.
SpringWorks Therapeutics Annual Long Term Debt
(Millions of US $) |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
SpringWorks Therapeutics Quarterly Long Term Debt
(Millions of US $) |
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.907B |
$0.035B |
|
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
|
